https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%8F%B2%E6%B3%BD%E5%A6%A5%E5%8D%95%E6%8A%97
菲泽妥单抗 - 版本历史
2026-04-21T12:07:14Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%8F%B2%E6%B3%BD%E5%A6%A5%E5%8D%95%E6%8A%97&diff=313181&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T02:54:14Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[菲泽妥单抗]]([[Felzartamab]])</strong>，研发代码为<strong>[[MOR202]]</strong>，是一种高亲和力、全人源化单克隆抗体，特异性靶向细胞表面抗原<strong>[[CD38]]</strong>。该药物最初由[[MorphoSys]]开发，现归属于<strong>[[勃健]]([[Biogen]])</strong>旗下（通过收购[[HI-Bio]]获得）。与传统的[[CD38]]单抗主要用于血液肿瘤不同，[[Felzartamab]]在2026年的临床定位核心在于**[[免疫介导性肾病]]**。它通过精准耗竭产生致病抗体的<strong>[[浆细胞]]</strong>及<strong>[[浆母细胞]]</strong>，从源头上阻断自身免疫损伤。在2026年的治疗规范中，[[Felzartamab]]已被视为治疗<strong>[[IgA肾病]]</strong>及<strong>[[膜性肾病]]</strong>最具前景的“疾病修饰疗法”之一。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">菲泽妥单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Felzartamab (MOR202)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Felzartamab binding to CD38 epitope</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">作用靶点：[[CD38]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">952</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P28074</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">人源化IgG1κ单抗</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">静脉输注([[IV]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要药企</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">勃健([[Biogen]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">肾病领域突破性药物</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：耗竭致病浆细胞</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Felzartamab]]通过识别浆细胞表面高度表达的[[CD38]]分子，启动多重免疫杀伤机制。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>免疫介导杀伤：</strong><br />
通过结合[[CD38]]，[[Felzartamab]]激活<strong>[[抗体依赖性细胞介导的细胞毒性]]([[ADCC]])</strong>及<strong>[[抗体依赖性细胞吞噬作用]]([[ADCP]])</strong>，通过NK细胞和巨噬细胞高效清除目标浆细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>清除抗体工厂：</strong><br />
与靶向B细胞的CD20单抗不同，[[Felzartamab]]能打击B细胞发育的终末阶段——<strong>[[浆细胞]]</strong>。这些细胞正是产生<strong>[[抗PLA2R抗体]]</strong>（膜性肾病）或<strong>[[Gd-IgA1]]</strong>（IgA肾病）的源头。</li><br />
<li style="margin-bottom: 12px;"><strong>2026 深度发现：</strong><br />
研究证实[[Felzartamab]]能显著降低骨髓中的<strong>[[长寿浆细胞]]</strong>库，这一效应在实现慢性自身免疫性肾病的长期缓解中起到决定性作用。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床循证与研究图谱</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026核心证据(研究名称)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[原发性膜性肾病]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">M-PROVE研究：显著提高蛋白尿完全缓解率及抗体转阴速度。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>快速起效</strong>。优于传统利妥昔单抗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[IgA肾病]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">IGNAZ研究：治疗5个月后显著降低[[uPCR]]，保护肾功能。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>精准打击</strong>。靶向致病性半乳糖缺失型IgA1产生。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[抗体介导的排斥]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对肾移植术后慢性[[AMR]]，展现了改善移植物存活的潜力。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">填补移植领域难治性排斥的治疗空白。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：精准滴定与管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Felzartamab]]在临床应用中强调“平衡耗竭”策略，以最大限度减少免疫缺陷风险：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>阶段化给药方案：</strong>2026年专家共识推荐先进行为期9周的强化诱导，随后转入每4-8周一次的维持治疗，旨在确保持续清空病理性浆细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>[[输注相关反应]]管理：</strong>首次给药建议配合预防性使用地塞米松及抗组胺药，以降低[[IRR]]发生率。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫球蛋白监测：</strong>治疗期间需定期检测血清<strong>[[总IgG]]</strong>水平。2026指南明确，若IgG水平持续过低，需考虑预防性补充[[IVIG]]或延长给药间隔。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CD38]]：</strong>一种在浆细胞上高度表达的外酶，[[Felzartamab]]的核心攻击位点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[长寿浆细胞]]([[LLPCs]])：</strong>存活于骨髓中的致病抗体“种子”，是普通免疫抑制剂无法触及的靶区。</li><br />
<li style="margin-bottom: 8px;"><strong>[[达雷妥尤单抗]]：</strong>全球首款上市的[[CD38]]单抗，为[[Felzartamab]]在肾病领域的开发提供了理论先行。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Mezagitamab]]：</strong>武田研发的同类竞争药物，目前正与[[Felzartamab]]展开头对头研究。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Dahan K,et al.(2024/2025Revision).</strong> <em>Felzartamab in antibody-mediated renal diseases:Long-term follow-up of the M-PROVE trial.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项具有里程碑意义的研究展示了[[CD38]]靶向策略在实现膜性肾病深度缓解方面的代际优势。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[Biogen]]Inc.(2026Update).</strong> <em>Integrating plasma cell depletion into the treatment paradigm of IgA Nephropathy:2026 Consensus Statement.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年最新综述论证了[[Felzartamab]]作为IgA肾病一线高危患者联合用药的必要性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
菲泽妥单抗 (Felzartamab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CD38]]•[[BCMA]]•[[BlyS]]•[[APRIL]]•[[FcRn]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[膜性肾病]]•[[IgA肾病]]•[[多发性骨髓瘤]]•[[SLE]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心临床</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IGNAZ研究]]•[[M-PROVE研究]]•[[ROCKY试验]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">监测指标</td><br />
<td style="padding: 10px 15px; color: #334155;">[[抗PLA2R滴度]]•[[24h尿蛋白]]•[[eGFR]]•[[IgG水平]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166